Oramed Pharmaceuticals (ORMP) Non-Current Assets (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Non-Current Assets came in at $200.7 million in Q1 2026, up 1149.44% YoY from $16.1 million in Q1 2025, and up 105.65% on a QoQ basis from $97.6 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Non-Current Assets (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Non-Current Assets data on file, last reported at $200.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 1149.44% year-over-year to $200.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.7 million (up 1149.44% YoY) and the FY2025 annual result came in at $97.6 million, up 709.43% from the prior year.
- Non-Current Assets grew to $200.7 million in Q1 2026, from $97.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $200.7 million in Q1 2026 to a low of $4.3 million in Q3 2022.
- A 5-year average of $43.6 million and a median of $27.4 million in 2022 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 1193.97% in 2023, down 83.87% in 2023.
- Tracing ORMP's Non-Current Assets over 5 years: stood at $4.5 million in 2022, then surged by 1178.78% to $58.0 million in 2023, then plunged by 79.2% to $12.1 million in 2024, then soared by 709.43% to $97.6 million in 2025, then soared by 105.65% to $200.7 million in 2026.
- The last three Non-Current Assets figures came in at $200.7 million (Q1 2026), $97.6 million (Q4 2025), and $84.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 316.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 316.24 Mn |
| Mar 31, 2026 | 200.70 Mn |
| Dec 31, 2025 | 97.59 Mn |
| Sep 30, 2025 | 84.38 Mn |
| Jun 30, 2025 | 62.66 Mn |
| Mar 31, 2025 | 16.06 Mn |
| Dec 31, 2024 | 12.06 Mn |
| Sep 30, 2024 | 22.31 Mn |
| Jun 30, 2024 | 30.95 Mn |
| Mar 31, 2024 | 26.56 Mn |
| Dec 31, 2023 | 57.97 Mn |
| Sep 30, 2023 | 55.19 Mn |
| Jun 30, 2023 | 5.34 Mn |
| Mar 31, 2023 | 4.62 Mn |
| Dec 31, 2022 | 4.53 Mn |
| Sep 30, 2022 | 4.27 Mn |
| Jun 30, 2022 | 27.42 Mn |
| Mar 31, 2022 | 28.66 Mn |
| Nov 30, 2021 | 30.12 Mn |
| Aug 31, 2021 | 32.66 Mn |